News

Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and ...
Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...
In a phase 2 study, 52% of patients treated with Bria-IMT plus a checkpoint inhibitor for metastatic breast cancer were alive at one year.
Amid new regulations, changes in tariffs, supply chain disruptions, we look at how CDMOs can remain at the forefront of ...
BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care ...
The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market for the TROP2-targeting ...
Sara M. Tolaney, MD, MPH, discusses new data from the ASCENT-04 trial and their implications for community oncologists.
Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...
BriaCell's most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients11 patients remain alive as of recent contact, including ...
Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine ...
The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences' magrolimab, the centre piece of its $4.9 billion acquisition of Forty Seven in 2020. The regulatory move applies ...
New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.